Journals / Marmara Pharmaceutical Journal / 2018 / Cilt: 22 - Sayı: 4

Development of a validated HPLC method for simultaneous determination of olanzapine and aripiprazole in human plasma

Pages
493–501
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Robustness of the method and the stability of analytes were also investigated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A simple and rapid HPLC method was developed and validated for simultaneous determination of two antipsychotic drugs, olanzapine and aripiprazole, in spiked human plasma.
📊
Key Findings & Data:Separation was achieved on a monolithic column (Rp-18, 100-4.6 mm) set at 35°C with a flow rate of 0.8 ml/min.
💡
Conclusion & Impact:Robustness of the method and the stability of analytes were also investigated.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

A simple and rapid HPLC method was developed and validated for simultaneous determination of two antipsychotic drugs, olanzapine and aripiprazole, in spiked human plasma. Optimization studies were performed using experimental design approach. The most important analysis parameters were selected using fractional factorial design and optimum levels of these parameters were determined with Box-Behnken design. Separation was achieved on a monolithic column (Rp-18, 100-4.6 mm) set at 35°C with a flow rate of 0.8 ml/min. Gradient elution was performed with a mobile phase consisting of phosphate buffer (pH 3.14, 20 mM) and acetonitrile. Retention times of olanzapine and aripiprazole were 2.34 and 6.90 minutes, respectively. The method was linear in the range of 0.125-50.0 µg/ml for olanzapine and 0.500-50.0 µg/ml for aripiprazole. The quantification limits for olanzapine and aripiprazole were found 0.069 and 0.498 µg/ml, respectively. The method was found accurate and precise based on recovery values, which were between 99-102% and relative standard deviations, which were lower than 2%. Robustness of the method and the stability of analytes were also investigated.

🔖

Cite This Article

KARACA, S. A., YENİCELİ, D. U. (2018). Development of a validated HPLC method for simultaneous determination of olanzapine and aripiprazole in human plasma. Marmara Pharmaceutical Journal, Cilt: 22 - Sayı: 4, 493–501. https://ajindex.com/articles/283734

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Konopaske GT, Coyle JT. Schizophrenia. In: Zigmond MJ, Coyle JT, Rowland L. (Eds). Neurobiology of Brain Disorders. Academic Press, San Diego, 2015, pp. 639-654. [CrossRef] [2] Volk DW, Lewis DA. Schizophreni.In: Rosenberg R, Pascual J. (Eds). Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease (Fifth Edition). Academic Press, Boston, 2015, pp. 1293-1299. [CrossRef] [3] Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry. 2010; 23(2): 103- 111. [CrossRef] [4] Patteet L, Morrens M, Maudens KE, Niemegeers P, Sabbe B, Neels H. Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit. 2012; 34(6): 629-651. [CrossRef] [5] Duggal HS. Aripirazole—Olanzapine combination for treatment of schizophrenia. Can J Psychiatry. 2004; 49(2): 151. [CrossRef] [6] Chen CH, Huang MC, Lu ML. Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients. J Clin Psychopharmacol. 2007; 27(5): 516-517. [CrossRef] [7] Englisch S, Weinbrenner A, Inta D, Zink M. Aripiprazole for the management of olanzapine-induced weight gain. Pharmacopsychiatry. 2009; 42(04): 166-167. [CrossRef] [8] Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol. 2009; 29(2): 165-169. [CrossRef] [9] Schönfelder S, Schirmbeck F, Waltereit R, Englisch S, Zink M. Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia. Clin Neuropharmacol. 2011; 34(6): 256-257. [CrossRef] [10] Aggarwal H, Kumar P. Aripiprazole for olanzapine-induced symptomatic hyperprolactinemia. Indian J Pharmacol. 2010; 42(1): 57-61. [CrossRef] [11] Patteet L, Cappelle D, Maudens KE, Crunelle CL, Sabbe B, Neels H. Advances in detection of antipsychotics in biological matrices. Clin Chim Acta. 2015; 441: 11-22. [CrossRef] [12] Dusci LJ, Peter Hackett L, Fellows LM, Ilett KF. Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 773(2): 191-197. [CrossRef] [13] Olesen OV, Linnet K. Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. J Chromatogr B Biomed Sci Appl. 1998; 714(2):